@invIOs_com

Developing tomorrow's cancer therapies, today.

 Vienna, Austria
invios.com
Joined December 2021
  • Tweets94
  • Following126
  • Followers43
46Media
Exciting news from the labs! Our lead small molecule program, #INV501, has demonstrated strong preclinical proof of concept with promising results against various solid tumor types. Today we're announcing some of our results for the first time: lnkd.in/dpRq6C_J 🧵 (1/5)

LinkedIn

This link will take you to a page that’s not on LinkedIn

lnkd.in
1
2
1
709
We presented some of these significant data via a poster session at the recent European Association for Cancer Research (EACR) congress in Turin. You can also find our #EACR2023 abstract in the conference's online database: lnkd.in/djhHSDUS (4/5)
1
1
559
We are excited by INV501's potential and the prospects for eventual development in a patient-friendly format such as a pill or capsule. Much remains to be done, but preliminary testing in other solid tumor indications is already affirming this novel compound's potential. (5/5)
1
400
Mini-🧵 Ahead of our AGM, we published our first-ever digital update to showcase invIOs's progress since launching in 2022: reportery.io/reports/invios/…  It’s been an exciting first phase in our mission to bring new treatment options to cancer patients. A few highlights 👇 (1/4)
1
2
1
669
more replies
👩‍🏫 We showcased promising data at three major scientific congresses in Europe and the US, and presented at more than 20 events 👏  Our excellent team now numbers 38 people, of whom two thirds are female, including numerous senior management positions (3/4)
1
1
350
Read the full report here to discover more of the invIOs story: reportery.io/reports/invios/… #invIOs #biotech #immunooncology #oncology #digitalcommunications #digitalreporting #diversity #researchbeatscancer #sciencealwayswins (4/4)
1
371
A pleasure to join the great and the good of Austria's capital markets community at Palais Niederösterreich for the #WienerBörsePreis 2023. Many thanks to the @wiener_boerse team for a fantastic evening, and congratulations to all the winners! #capitalmarkets #biotech #IPO
1
1
489
🇺🇸 Just a few days to go to #ASCO23! Our CMSO Romana Gugenberger and Head of Clinical Development Sarah Bischof will be flying the flag for invIOs at the @ASCO Annual Meeting – get in touch if you'd like to meet up. #invIOs #immunooncology #clinicalresearch #researchbeatscancer
1
455
🇺🇸 Looking forward to #BIO2023 on June 5-8 – one of the events of the #biotech year. #StandUpForScience is a great line to highlight the true value of the #innovations that #biotechnology creates for patients worldwide. Get in touch for meetings during the event! #partnering
3
2
510
We were privileged to welcome Professor Christoph Zielinski @cczielinski, one of Europe's leading medical oncologists, for a guest lecture on ICIs, biomarkers and the current state of the art in treating multiple tumors. More in our latest blog post: linkedin.com/pulse/lessons-f…

Lessons from the clinic: Checkpoint blockade, biomarkers, and the future of individualized solid...

We were privileged to welcome Professor Christoph Zielinski as our latest speaker in the invIOs Innovation Lectures. One of Europe's most distinguished medical oncologists, Professor Zielinski shared...

linkedin.com
3
1
6
1,097
🇦🇹 Don't miss #AustrianLifeScienceDay next week for some fascinating discussions around the future of healthcare, the development of personalised medicine and the growth of Austria's #biotech sector. @lifesciencevie
This Post is from an account that no longer exists. Learn more
1
1
601
Aprils is Head and Neck Cancer Awareness month – an opportunity to look at the importance of early detection as well as the development of novel treatments for solid tumors #headandneck #headandneckcancer #cancerawareness #getchecked #biotech #immunooncology #immunotherapy
1
1
2
387
Head and neck is the sixth most common cancer type worldwide, with more than 890,000 cases every year. The survival rate is more than 80% if the cancer is caught early, according to @hncalliance #headandneck #getchecked #immunooncology #cancerawareness #headandneckcancer
1
2
1
357
#invIOs is working to develop novel cancer therapies that empower patients' immune systems to fight back against solid tumors including #HNSCC: linkedin.com/pulse/getting-a… #headandneck #getchecked #immunooncology #cancerawareness #biotech #immunotherapies #headandneckcancer #APN401

Getting ahead in the fight against solid tumors

April is an awareness month for head and neck cancer – the sixth most common cancer type worldwide. Despite some advances in treatment, survival rates have improved only modestly over the past three...

linkedin.com
1
2
347
Six patients total were treated in a multicenter, open-label, phase 1b feasibility trial (NCT03087591) evaluating 2 increasing dose levels of APN401. #AACR23 Read more: ow.ly/R6NN50NPwFr

Cbl-b-Targeted Cell Therapy Controls Disease in 2 Patients With Solid Tumors | CGTlive®

Overall, 6 patients were treated in a feasibility study for a disease control rate of 33.3%.

cgtlive.com
2
1
440
APN401, an autologous cell therapy that silences Casitas B-lineage lymphoma-b (Cbl-b) in peripheral mononuclear cells (PBMCs), induced stable disease (SD) in 2 patients with advanced, metastatic solid tumors. ow.ly/a59U50NPzIn

Cbl-b-Targeted Cell Therapy Controls Disease in 2 Patients With Solid Tumors | CGTlive®

Overall, 6 patients were treated in a feasibility study for a disease control rate of 33.3%.

cgtlive.com
2
1
1,072
Looking forward to presenting the latest from our innovative #cancer #immunotherapy programs at #LSXWorld in #London. Our presentation is at 11:30 a.m. on 3 May during the Biotech Showcase Agenda. Get in touch for meetings during the event! #biotech #innovation #immunooncology
2
1
467
Load more